Sensei Biotherapeutics (NASDAQ:FTH) Raised to Hold at Wall Street Zen

Sensei Biotherapeutics (NASDAQ:FTH) was upgraded by investment analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research report issued on Saturday.

Several other research firms also recently commented on FTH. Loop Capital set a $50.00 price objective on Sensei Biotherapeutics in a report on Thursday, May 28th. HC Wainwright reiterated a “buy” rating and issued a $60.00 target price on shares of Sensei Biotherapeutics in a report on Tuesday, August 11th. Citigroup began coverage on shares of Sensei Biotherapeutics in a research report on Friday, May 22nd. They issued a “buy” rating and a $55.00 price target for the company. Robert W. Baird began coverage on shares of Sensei Biotherapeutics in a research note on Friday, June 26th. They set an “outperform” rating and a $57.00 price target for the company. Finally, Raymond James Financial began coverage on shares of Sensei Biotherapeutics in a report on Friday, July 31st. They set an “outperform” rating and a $56.00 price objective on the stock. One research analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average target price of $55.00.

Sensei Biotherapeutics Price Performance

Shares of Sensei Biotherapeutics stock opened at $32.00 on Friday. Sensei Biotherapeutics has a one year low of $7.45 and a one year high of $37.90. The company has a market cap of $826.88 million, a price-to-earnings ratio of -0.23 and a beta of -0.25. The company has a 50-day moving average price of $27.27.

Sensei Biotherapeutics (NASDAQ:FTH) last announced its quarterly earnings results on Tuesday, August 4th. The company reported ($2.84) earnings per share (EPS) for the quarter, topping the consensus estimate of ($5.04) by $2.20. On average, sell-side analysts predict that Sensei Biotherapeutics will post -13.18 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, major shareholder James Peyer sold 25,000 shares of the firm’s stock in a transaction that occurred on Monday, June 1st. The stock was sold at an average price of $20.02, for a total value of $500,500.00. Following the transaction, the insider owned 130,142 shares in the company, valued at $2,605,442.84. This trade represents a 16.11% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Anand Kiran Parikh bought 2,806 shares of the business’s stock in a transaction that occurred on Monday, June 22nd. The shares were bought at an average cost of $19.76 per share, for a total transaction of $55,446.56. Following the transaction, the chief executive officer owned 764,234 shares of the company’s stock, valued at $15,101,263.84. The trade was a 0.37% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last ninety days, insiders purchased 49,494 shares of company stock valued at $1,188,822. Corporate insiders own 7.00% of the company’s stock.

Institutional Investors Weigh In On Sensei Biotherapeutics

Institutional investors and hedge funds have recently bought and sold shares of the stock. Vivo Capital LLC bought a new position in Sensei Biotherapeutics during the 1st quarter valued at $22,758,000. Alyeska Investment Group L.P. bought a new stake in shares of Sensei Biotherapeutics in the 2nd quarter worth $3,610,000. Stempoint Capital LP bought a new stake in shares of Sensei Biotherapeutics in the 1st quarter worth $4,188,000. Bank of America Corp DE raised its holdings in shares of Sensei Biotherapeutics by 10,692.5% in the first quarter. Bank of America Corp DE now owns 33,025 shares of the company’s stock valued at $1,041,000 after purchasing an additional 32,719 shares during the last quarter. Finally, Renaissance Technologies LLC raised its holdings in shares of Sensei Biotherapeutics by 178.2% in the first quarter. Renaissance Technologies LLC now owns 32,041 shares of the company’s stock valued at $1,010,000 after purchasing an additional 20,525 shares during the last quarter. 10.50% of the stock is owned by hedge funds and other institutional investors.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.